Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

EP102: Pharmacological Inhibition of METTL3 Elicits Tumor Growth Inhibition In Vivo and Demonstrates Synergy with Venetoclax in Various AML Models

Graeme Fraser, Catherine Sorlet, Nicolas Parmentier, Anne-France Hartiel, Sandrine Hospied, Clement Mompied, Genevieve Absil, Killian Oukoloff, Guillaume Dutheuil

Blood (2023) 142 (Supplement 1): 2263.

https://doi.org/10.1182/blood-2023-189993

Published: 2023

Journal Articles

Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphomas

Amaris K. Balitsky, Gregory R Pond, Graeme Fraser, Tom Kouroukis, Stephen Ronan Foley

Blood (2022) 140 (Supplement 1): 8036–8037.

https://doi.org/10.1182/blood-2022-165674

Published: 2022

Journal Articles

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 27–30.

https://doi.org/10.1182/blood-2020-136692

Published: 2020

Journal Articles

Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study

Richard Greil, MD, Graeme Fraser, Brian Leber, MD, Reinhard Marks, Giulia Quaresmini, Jan Moritz Middeke, Gianpietro Semenzato, William Schary, Michelle Boyer, Madlaina Breuleux, PhD DAS, Noelle Crompton, Kathryn Humphrey, Paula Marlton

Blood (2018) 132 (Supplement 1): 5548.

https://doi.org/10.1182/blood-2018-99-118148

Published: 2018

Journal Articles

Recurrent Gene Mutations and Clinical Outcome in the Context of Lenalidomide Treatment of Relapsed/Refractory CLL — Results from Multicenter Phase II Trial CLL-009

Veronika Opatrna, MD, Eugen Tausch, MD, Graeme Fraser, MD, Anne-Sophie Michallet, MD PhD, Peter Hillmen, MBChB, PhD, Jan Dürig, MD, Matt Kalaycio, MD, John G. Gribben, MDDSc FMedSci, Thomas J. Kipps, MD, Brendan Purse, Jennie Zhang, Sabine De Bedout, Asher A. Chanan-Khan, MD, Michael J. Hallek, MD, Clemens-Martin Wendtner, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 4311.

https://doi.org/10.1182/blood.V130.Suppl_1.4311.4311

Published: 2017

Journal Articles

Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis

Blood (2017) 130 (Supplement 1): 1743.

https://doi.org/10.1182/blood.V130.Suppl_1.1743.1743

Published: 2017

Journal Articles

11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

Blood (2016) 128 (22): 2042.

https://doi.org/10.1182/blood.V128.22.2042.2042

Published: 2016

Journal Articles

Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial

Blood (2016) 128 (22): 4403.

https://doi.org/10.1182/blood.V128.22.4403.4403

Published: 2016

Journal Articles

The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis

Darryl P. Leong, François Caron, Christopher Hillis, Annie Duan, Jeff S. Healey, Graeme Fraser, Deborah Siegal

Blood (2016) 128 (1): 138–140.

https://doi.org/10.1182/blood-2016-05-712828

Published: 2016

Journal Articles

Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Blood (2015) 126 (23): 2938.

https://doi.org/10.1182/blood.V126.23.2938.2938

Published: 2015

Journal Articles

Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials

Peter Hillmen, MB, ChB, PhD, Graeme Fraser, MDFRCPC, Jeffrey Jones, MD MPH, Simon Rule, MD, Susan O'Brien, MD, Marie Sarah Dilhuydy, MD, Ulrich Jaeger, MD, Sebastian Grosicki, MD PhD, Florence Cymbalista, MD PhD, Steven Sun, PhD, Joi Ninomoto, PharmD, Michelle Mahler, MD, Mei Cheng, PhD, Joris Diels, Fong Clow, ScD, Mariya Salman, PhD, Danelle F. James, MD MAS, Angela Howes, PhD, Asher Chanan-Khan, MD

Blood (2015) 126 (23): 2944.

https://doi.org/10.1182/blood.V126.23.2944.2944

Published: 2015

Journal Articles

Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab

Blood (2015) 126 (23): 2936.

https://doi.org/10.1182/blood.V126.23.2936.2936

Published: 2015

Journal Articles

Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial

Asher Chanan-Khan, MD, Paula Cramer, MD, Graeme Fraser, MDFRCPC, Rodrigo Santucci Silva, MD, Sebastian Grosicki, MD PhD, Aleksander Pristupa, MD, Marie Sarah Dilhuydy, MD, Andre Goy, MD, Anthony R. Mato, MD MSCE, Rajendra Damle, PhD, Charles Phelps, MS, Michelle Mahler, MD, Mariya Salman, PhD, Michael Schaffer, PhD, Angela Howes, PhD, Sriram Balasubramanian, PhD

Blood (2015) 126 (23): 1732.

https://doi.org/10.1182/blood.V126.23.1732.1732

Published: 2015

Journal Articles

Ibrutinib Plus Bendamustine/Rituximab (BR) Is Associated with Greater Reductions in Fatigue Than Placebo Plus BR Among Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Fatigue

Shana Traina, PhD, Graeme Fraser, MDFRCPC, Paula Cramer, MD, Rodrigo Santucci Silva, MD, Sebastian Grosicki, MD PhD, Marie Sarah Dilhuydy, MD, Michelle Mahler, MD, Mariya Salman, PhD, Angela Howes, PhD

Blood (2015) 126 (23): 267.

https://doi.org/10.1182/blood.V126.23.267.267

Published: 2015

Journal Articles

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Chronic Lymphocytic Leukemia: NCIC CTG Trial IND.193

Matthew D. Seftel, MDMPH FRCPC, John Kuruvilla, MD, Versha Banerji, MD, Graeme Fraser, MDFRCPC, Hao Xu, MSc, Jean Powers, MSc, Susan Crocker, PhD, Marcia Toguchi, PhD, John F Lyons, PhD, Lesley Seymour, MDPhD, Annette E Hay, MB ChB

Blood (2014) 124 (21): 5670.

https://doi.org/10.1182/blood.V124.21.5670.5670

Published: 2014

Journal Articles

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Andreas Bühler, Clemens Wendtner, MD, Michael Hallek, Thomas J. Kipps, MD, PhD, Laura Rassenti, PhD, Graeme Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Duerig, MD, Stephanie A. Gregory, Matt Kalaycio, MD, Therese Aurran-Schleinitz, Livio Trentin, Brendan Purse, Jennie Zhang, Jay Mei, MD, Stephan Stilgenbauer, MD

Blood (2013) 122 (21): 1638.

https://doi.org/10.1182/blood.V122.21.1638.1638

Published: 2013

Journal Articles

Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Clemens Wendtner, MD, Michael Hallek, MD, Graeme Fraser, Anne-Sophie Michallet, MD, PhD, Peter Hillmen, Jan Duerig, Stephanie A. Gregory, MD, Matt Kalaycio, MD, Stephan Stilgenbauer, MD, Andreas Buehler, Thomas J. Kipps, MD, PhD, Brendan Purse, Jennie Zhang, Jay Mei, MD, PhD, Asher Chanan-Khan, MD

Blood (2012) 120 (21): 3925.

https://doi.org/10.1182/blood.V120.21.3925.3925

Published: 2012

Journal Articles

Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study)

Clemens Wendtner, MD, Graeme Fraser, Stuart L. Goldberg, MD, Adrian JC Bloor, PhD, FRCP, FRCPath, Stephan Stilgenbauer, Florence Cymbalista, Thomas Kipps, Brendan Purse, Jennie Zhang, Jay Mei, MD, PhD, Asher Chanan-Khan

Blood (2011) 118 (21): 2859.

https://doi.org/10.1182/blood.V118.21.2859.2859

Published: 2011

Journal Articles

Comparison of Comorbidity Scores and the Impact of Comorbidities on Length of Stay and Survival in Patients with Non−Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplant

Kylie Lepic, MD, FRCPC, Ann Benger, MD, FRCP(C), Ronan Foley, MD, FRCPC, Graeme Fraser, Deborah Marcellus, MD, Michelle Saunders-Roy, RN, Michael Trus, MD, PhD, FRCPC, Anita Adams, RN(EC), MN, NP, CPMHN(C), Kari Kolm, RN(EC), MN, NP, Jennifer Wiernikowski, MN, NP, CON(C), C. Tom Kouroukis, MD, MSc, FRCPC

Blood (2011) 118 (21): 2091.

https://doi.org/10.1182/blood.V118.21.2091.2091

Published: 2011

Journal Articles

The Frequency and Clinical Significance of Thrombocytopenia Complicating Critical Illness: A Systematic Review

Philip LY Hui, MD, Deborah J Cook, MD, Wendy Lim, MD, MSc, Graeme Fraser, MD, Donald M. Arnold, MD

Blood (2010) 116 (21): 4664.

https://doi.org/10.1182/blood.V116.21.4664.4664

Published: 2010

NARROW

EP102: Pharmacological Inhibition of METTL3 Elicits Tumor Growth Inhibition In Vivo and Demonstrates Synergy with Venetoclax in Various AML Models

Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphomas

A Prospective Economic Analysis of Canadian Cancer Trials Group Clc.2/Alliance A041202: A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study

Recurrent Gene Mutations and Clinical Outcome in the Context of Lenalidomide Treatment of Relapsed/Refractory CLL — Results from Multicenter Phase II Trial CLL-009

Incidence of and Risk Factors for Major Hemorrhage in Patients Treated with Ibrutinib: Results from an Integrated Analysis

11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies

Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial

The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis

Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials

Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab

Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial

Ibrutinib Plus Bendamustine/Rituximab (BR) Is Associated with Greater Reductions in Fatigue Than Placebo Plus BR Among Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Fatigue

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Chronic Lymphocytic Leukemia: NCIC CTG Trial IND.193

TP53 Mutation or Deletion and Efficacy with Single-Agent Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study)

Comparison of Comorbidity Scores and the Impact of Comorbidities on Length of Stay and Survival in Patients with Non−Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplant

The Frequency and Clinical Significance of Thrombocytopenia Complicating Critical Illness: A Systematic Review

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only